Cargando…
Coronary spastic angina in a multiple myeloma patient treated with bortezomib, lenalidomide, and dexamethasone
Adverse cardiovascular events have been reported in patients with multiple myeloma. We present a case of coronary spastic angina during combination therapy with bortezomib, lenalidomide, and dexamethasone for multiple myeloma. A 70-year-old man, newly diagnosed with multiple myeloma, was admitted to...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese College of Cardiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195564/ https://www.ncbi.nlm.nih.gov/pubmed/32373247 http://dx.doi.org/10.1016/j.jccase.2020.02.002 |
Sumario: | Adverse cardiovascular events have been reported in patients with multiple myeloma. We present a case of coronary spastic angina during combination therapy with bortezomib, lenalidomide, and dexamethasone for multiple myeloma. A 70-year-old man, newly diagnosed with multiple myeloma, was admitted to our hospital at his fifth therapy cycle due to exertional chest pain. Coronary angiography revealed diffuse spasm in the left coronary artery, which normalized after intracoronary injection of nitroglycerin. Calcium channel blockers were effective in treating his coronary spastic angina and the patient resumed treatment for multiple myeloma. This case highlights the importance of being aware of the possibility of coronary spastic angina when combination therapy with bortezomib, lenalidomide, and dexamethasone is initiated. <Learning objective: Combination therapy with bortezomib, lenalidomide, and dexamethasone has improved overall survival of multiple myeloma patients. However, these drugs can induce coronary spastic angina. Calcium channel blockers may be effective for coronary spastic angina and allow patients to continue multiple myeloma treatment.> |
---|